Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

382 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer.
Yoshino T, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, Yamaguchi K, Nishina T, Wainberg Z, Elez E, Rodriguez J, Fakih M, Ciardiello F, Saxena K, Kobayashi K, Bako E, Okuda Y, Meinhardt G, Grothey A, Siena S; DESTINY-CRC01 investigators. Yoshino T, et al. Among authors: grothey a. Nat Commun. 2023 Jun 7;14(1):3332. doi: 10.1038/s41467-023-38032-4. Nat Commun. 2023. PMID: 37286557 Free PMC article.
Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation.
Cohen R, Raeisi M, Chibaudel B, Yoshino T, Shi Q, Zalcberg JR, Adams R, Cremolini C, Grothey A, Mayer RJ, Van Cutsem E, Tabernero J, Bando H, Misumi T, Overman MJ, André T, de Gramont A. Cohen R, et al. Among authors: grothey a. Eur J Cancer. 2024 Mar;199:113537. doi: 10.1016/j.ejca.2024.113537. Epub 2024 Jan 15. Eur J Cancer. 2024. PMID: 38241818
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01.
Siena S, Raghav K, Masuishi T, Yamaguchi K, Nishina T, Elez E, Rodriguez J, Chau I, Di Bartolomeo M, Kawakami H, Suto F, Koga M, Inaki K, Kuwahara Y, Takehara I, Barrios D, Kobayashi K, Grothey A, Yoshino T. Siena S, et al. Among authors: grothey a. Nat Commun. 2024 Nov 25;15(1):10213. doi: 10.1038/s41467-024-53223-3. Nat Commun. 2024. PMID: 39587050 Free PMC article. Clinical Trial.
Improving Rectal Cancer Treatments 1 Study at a Time.
VanderWalde N, Grothey A. VanderWalde N, et al. Among authors: grothey a. JAMA Netw Open. 2023 Oct 2;6(10):e2340223. doi: 10.1001/jamanetworkopen.2023.40223. JAMA Netw Open. 2023. PMID: 37902759 Free article. No abstract available.
Corrigendum to "Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3369 patients in the ARCAD database" Eur J Cancer. 2023 Jan;178:162-170.
Margalit O, Harmsen WS, Shacham-Shmueli E, Voss MM, Boursi B, Wagner AD, Cohen R, Olswold CL, Saltz LB, Goldstein DA, Hurwitz H, Tebbutt NC, Kabbinavar FF, Adams RA, Chibaudel B, Grothey A, Yoshino T, Zalcberg J, de Gramont A, Shi Q, Lenz HJ. Margalit O, et al. Among authors: grothey a. Eur J Cancer. 2023 Nov;194:113339. doi: 10.1016/j.ejca.2023.113339. Epub 2023 Sep 28. Eur J Cancer. 2023. PMID: 37813779 No abstract available.
Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer.
Ducreux M, Tabernero J, Grothey A, Arnold D, O'Dwyer PJ, Gilberg F, Abbas A, Thakur MD, Prizant H, Irahara N, Tahiri A, Schmoll HJ, Van Cutsem E, de Gramont A. Ducreux M, et al. Among authors: grothey a. Eur J Cancer. 2023 May;184:137-150. doi: 10.1016/j.ejca.2023.01.023. Epub 2023 Feb 4. Eur J Cancer. 2023. PMID: 36921494 Free article. Clinical Trial.
Phase I-II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumors.
Tsimberidou AM, Grothey A, Sigal D, Lenz HJ, Hochster HS, Chao Y, Bai LY, Yen CL, Xu D, Saville MW. Tsimberidou AM, et al. Among authors: grothey a. Cancer Chemother Pharmacol. 2024 Dec;94(6):787-798. doi: 10.1007/s00280-024-04714-z. Epub 2024 Sep 23. Cancer Chemother Pharmacol. 2024. PMID: 39311947 Free PMC article. Clinical Trial.
Herpes simplex virus 1 inhibits phosphorylation of RNA polymerase II CTD serine-7.
Whisnant AW, Dyck Dionisi O, Salazar Sanchez V, Rappold JM, Djakovic L, Grothey A, Marante AL, Fischer P, Peng S, Wolf K, Hennig T, Dölken L. Whisnant AW, et al. Among authors: grothey a. J Virol. 2024 Oct 22;98(10):e0117824. doi: 10.1128/jvi.01178-24. Epub 2024 Sep 24. J Virol. 2024. PMID: 39316591 Free PMC article.
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.
Cohen R, Raeisi M, Chibaudel B, Shi Q, Yoshino T, Zalcberg JR, Adams R, Cremolini C, Van Cutsem E, Heinemann V, Tabernero J, Punt CJA, Arnold D, Hurwitz HI, Douillard JY, Venook AP, Saltz LB, Maughan TS, Kabbinavar F, Bokemeyer C, Grothey A, Mayer RJ, Kaplan R, Tebbutt NC, Randolph Hecht J, Giantonio BJ, Díaz-Rubio E, Sobrero AF, Peeters M, Koopman M, Goldberg RM, Andre T, de Gramont A. Cohen R, et al. Among authors: grothey a. Eur J Cancer. 2024 Aug;207:114160. doi: 10.1016/j.ejca.2024.114160. Epub 2024 Jun 10. Eur J Cancer. 2024. PMID: 38896997
382 results